|1.||Adams, David J: 12 articles (02/2015 - 06/2004)|
|2.||Craik, David J: 12 articles (01/2015 - 06/2004)|
|3.||Lewis, Richard J: 9 articles (10/2015 - 06/2004)|
|4.||Alewood, Paul F: 6 articles (10/2015 - 11/2006)|
|5.||Vetter, Irina: 6 articles (10/2015 - 01/2012)|
|6.||Daly, Norelle L: 6 articles (03/2012 - 06/2004)|
|7.||Clark, Richard J: 6 articles (03/2012 - 03/2008)|
|8.||Kaas, Quentin: 4 articles (01/2015 - 12/2011)|
|9.||Berecki, Géza: 4 articles (01/2015 - 10/2008)|
|10.||McIntosh, J Michael: 4 articles (10/2014 - 03/2008)|
10/01/2015 - "A more comprehensive characterisation of the role of α9α10-nAChRs in pain is crucial for understanding the analgesic action of conotoxins and for improved drug design. "
12/01/2011 - "In this article, we discuss structural and biological studies on several classes of conotoxins that have potential as drug leads for the treatment of pain. "
10/01/2015 - "This receptor was first implicated in pain with the characterisation of conotoxin Vc1.1, which is highly selective for α9α10-nAChRs and is an efficacious analgesic in chronic pain models with restorative capacities and no reported side effects. "
03/01/2015 - "We confirmed that conotoxin lt14a administration resulted in antinociception activity using a mouse inflammatory pain model and a rat model of mechanically-induced pain. "
10/01/2014 - "Α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement."
|2.||Neuralgia (Stump Neuralgia)
09/01/2013 - "A major highlight was the development of an orally active cyclized conotoxin derivative that is highly efficacious in a rat model of neuropathic pain. "
09/01/2013 - "ω-conotoxins, such MVIIA and CVID are effective in neuropathic pain models. "
12/01/2006 - "A lead compound, ACV1 (conotoxin Vc1.1 from Conus victoriae), has entered Phase II clinical trials and is being developed for the treatment for neuropathic pain. "
01/01/2015 - "Cyclic α-conotoxin Vc1.1 (cVc1.1) is an orally active peptide with analgesic activity in rat models of neuropathic pain. "
05/01/2014 - "Antagonists of α9α10 nAChRs, like the α-conotoxin Vc1.1, have analgesic effects in neuropathic pain. "
12/01/2013 - "When administered at the acute painful stage, ω-conotoxin MVIIA (300pmol/site, i.t.) and Phα1β (300pmol/site, i.t.) prevented the worsening of chronic mechanical hyperalgesia. "
09/01/2013 - "All ω-conotoxins produced dose-dependent reduction in mechanical allodynia. "
06/01/2012 - "Intrathecal administration of α-conotoxins, Vc1.1, AuIB and MII into neuropathic rats reduced mechanical allodynia for up to 6 h without significant side effects. "
01/01/2012 - "The chronic intrathecal administration of GBP (100 µg/body per day) as well as ω-conotoxin MVIIA, an N-type Ca(2+)-channel blocker, completely suppressed allodynia, but did not attenuate the CD11b expression. "
01/01/2013 - "A single intrathecal injection of Phα1β reversibly inhibits CFA and CCI-induced mechanical hyperalgesia longer than a single injection of ω-conotoxin MVIIA. "
|4.||Schizophrenia (Dementia Praecox)
01/01/2011 - "Conotoxin has been proven to be effective in drug design and could be used to treat various disorders such as schizophrenia, neuromuscular disorders and chronic pain. "
03/15/2012 - "Here, the principles of conotoxin cyclization are illustrated with applications to the α- and χ- conotoxin classes, which have been implicated as leads for the treatment of pain and a range of other disorders including neuroprotection, schizophrenia, depression and cancer."
12/01/2014 - "One conotoxin family in particular, the α-conotoxins, acts on nicotinic acetylcholine receptors (nAChRs) which dysfunctions play important roles in pathologies such as epilepsy, myasthenic syndromes, schizophrenia, Parkinson's disease and Alzheimer's disease. "
12/01/2010 - "Most importantly, antagonism of the channel by the highly specific and potent Cav2.2 blocker ω-conotoxin MVIIA (ziconotide) produces clinical efficacy in the treatment of severe, intractable pain. "
05/01/2012 - "Among these, ω-conotoxin MVIIA (Prialt) is approved by the Food and Drug Administration (FDA) as an alternative intrathecal analgesic for the management of chronic intractable pain, particularly in patients refractory to opioids. "
|3.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|5.||Opioid Analgesics (Opioids)
|7.||Drosophila acetylcholine receptor alpha-subunit
|9.||Sodium Channels (Sodium Channel)
|10.||Calcium Channels (Calcium Channel)